SQZ-PBMC-HPV

In patients with incurable HPV16+ solid tumors treated with SQZ-PBMC-HPV, an increase in CD8+ T cell density within the tumor parenchyma was associated with superior disease control rate and overall survival. The product composition for patients with increased CD8+ T cell density was enriched for T cells.

SQZ-PBMC-HPV was well tolerated; 5.0 × 10 live cells/kg with double priming was chosen as the recommended Phase 2 dose. Multiple participants exhibited pharmacodynamic changes consistent with immune responses supporting the proposed mechanism of action for SQZ-PBMC-HPV, including patients previously refractory to checkpoint inhibitors.

P1, N=30, Completed, SQZ Biotechnologies | Active, not recruiting --> Completed | N=200 --> 30 | Trial completion date: Jun 2023 --> Feb 2023

P1, N=200, Active, not recruiting, SQZ Biotechnologies | Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Nov 2022 --> Mar 2023

P1 | "These antigen presenting cells (APC) were matured with CpG7909 and were not genetically modified . SQZ-PBMC-HPV-101 demonstrated clinical feasibility of the Cell Squeeze technology and favorable tolerability of engineered APCs . The study allows for the characterization of the immunogenicity of engineered APCs in humans . Preliminary results warrant the testing in combination with CPI ."